Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII

被引：25
|
作者：
Scharrer, I
Ehrlich, HJ
机构：
[1] Univ Hosp Frankfurt, Ctr Internal Med, D-60596 Frankfurt, Germany
[2] Baxter Hyland Immuno, Vienna, Austria
来源：
HAEMOPHILIA | 2001年 / 7卷 / 04期
关键词：
blood coagulation factor inhibitors; clinical trials; factor VIII; haemophilia A; incidence; recombinant proteins;
D O I：
10.1046/j.1365-2516.2001.00515.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
De novo inhibitor development is a rare event in PTPs switched from pdFVIII to rFVIII. Based on previously published data of clinical studies a change in FVIII product is unlikely to provoke inhibitor formation.
引用
收藏
页码：346 / 348
页数：3
相关论文
共 50 条
  • [1] INHIBITOR QUESTIONS - PLASMA-DERIVED FACTOR-VIII AND RECOMBINANT FACTOR-VIII
    BRAY, G
    ANNALS OF HEMATOLOGY, 1994, 68 : S29 - S34
  • [2] EPITOPE SPECIFICITY OF INHIBITOR ANTIBODIES FROM PATIENTS TREATED WITH RECOMBINANT OR PLASMA-DERIVED FACTOR-VIII
    SCANDELLA, D
    CORTER, S
    GOMPERTS, E
    HURST, D
    ESMON, P
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 557 - 557
  • [3] Effect of plasma-derived or recombinant factor VIII on inhibitor development: a systematic review
    Iorio, A.
    Halimeh, S.
    Goldenberg, N.
    Kenet, G.
    Young, G.
    Brandao, L.
    HAEMOPHILIA, 2010, 16 : 74 - 74
  • [4] Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates
    Scharrer, I
    Bray, GL
    Neutzling, O
    HAEMOPHILIA, 1999, 5 (03) : 145 - 154
  • [5] Inhibitor development and efficacy of recombinant vs. plasma-derived factor VIII concentrates in haemophilia A patients
    Siegmund, B.
    Richter, H.
    Pollmann, H.
    Orlovic, M.
    Gottstein, S. .
    Klamroth, R.
    HAEMOPHILIA, 2008, 14 : 51 - 51
  • [6] The increased demand for plasma-derived factor VIII in Italy
    Arcieri, Romano
    Calizzani, Gabriele
    Candura, Fabio
    Mannucci, Pier Mannuccio
    BLOOD TRANSFUSION, 2017, 15 (03) : 279 - 280
  • [7] Effect of plasma-derived or recombinant factor VIII on inhibitor development. A systematic review
    Iorio, A.
    Halimeh, S.
    Bidlingmaier, C.
    Ettingshausen, C. E.
    Gringeri, A.
    Holzhauer, S.
    Knoefler, R.
    Kreuz, W.
    Kurnik, K.
    Manner, D.
    Santagostino, E.
    Mannucci, P. M.
    Nowak-Goettl, U.
    HAEMOPHILIA, 2010, 16 (02) : 410 - 410
  • [8] Assessment of inhibitor risk after switching from plasma-derived factor VIII concentrate to recombinant factor VIII (Brasil-RFVIII: brazilian study of inhibitor linked to recombinant factor VIII)
    Prezotti, A.
    Montalvao, S.
    Marques, A.
    Ferreira, C.
    Oliveira, L.
    Villaca, P.
    Ferreira Filho, L.
    Lorenzato, C.
    Medina, S.
    Araujo, F.
    Ozelo, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 366 - 366
  • [9] Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better
    Mannucci, Pier Mannuccio
    BLOOD TRANSFUSION, 2010, 8 (04) : 288 - 291
  • [10] Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates
    Lin, Y
    Yang, X
    Chevrier, MC
    Craven, S
    Barrowcliffe, TW
    Lemieux, R
    Ofosu, FA
    HAEMOPHILIA, 2004, 10 (05) : 459 - 469
12345